This treatment significantly reduced brain levels of soluble, insoluble amyloid beta (Aβ) and phosphorylated Tau protein by ~40%, ~20% and ~ 80%, respectively, compared to untreated mice with AD phenotype. The gene discussed is MAPT; the disease is Alzheimer disease.